How biotech and diagnostics companies show a team that can take a drug or test from lab to approval: drugs brought to market, clinical and regulatory years.
Biotech Team Slide: Show Who Has Taken a Product Through the Clinic Before
A biotech product takes years of trials and regulatory review before it earns money, so investors read the team slide for one question above the others: has anyone here done this before? They look for people who have run clinical trials, dealt with regulators, got a product approved and raised money for it. This guide compares seven real team slides from decks tagged biotech in our library, from one that names an approved drug its CEO invented to one that crowds three groups of people into narrow columns.
TL;DR
Name the approvals and results, not only the years. Tiziana's CEO is "Inventor of TRULANCE® approved for Chronic constipation and IBS-C", and the slide says "3 team members independently brought 3 drugs to market". Greenwich LifeSciences shows a VP with "30 years of active involvement in over 200 clinical trials". BioTime and Athersys show years and past employers' logos, Interpace writes prose bios, mHealthPharma lists co-founders with little clinical experience, and Medgenics packs board, advisors and management into three dense columns.
Biotech team slides from real pitch decks
Each example shows the exact stored slide above its analysis and links to the full teardown. The clearest slides come first; weaker ones follow for contrast. Claims are as shown on the slides; comments are ours.
Tiziana Life Sciences team slide — slide 3
Drug developer, publicly listed. Slide titled "Key Members of Executive Team".
Tiziana Life Sciences deck, slide 3. Exact stored slide matched to this analysis.
Our analysis: The slide answers the main biotech question directly: people on this team have taken drugs to approval before.
Evidence and limitation: A named approved drug the CEO invented, a company sale with a value, and a summary box of what the team has achieved.
What a founder can adapt: Add a summary line like "3 team members brought 3 drugs to market" if it is true for your team.
Supporting analysis
What the deck claims: Kunwar Shailubhai, "CEO & CSO": "Co-founder, EVP & CSO of Synergy Pharmaceuticals, NASDAQ: SGYP", "Inventor of TRULANCE® approved for Chronic constipation and IBS-C", "VP, Callisto Pharmaceuticals", "Group Leader, Monsanto Co.". Gabriele Cerrone, "Executive Chairman": "Founder and chairman of two biotech companies with market cap over $2 B", "Inhibitex sale $2.5 B". Two non-executive directors. "Key Strengths of the Management Team": "Successful track record in biotechnology 'Bench to Market'", "3 team members independently brought 3 drugs to market".
Presentation choice: Approval experience is rare and hard to fake; naming the drug lets an investor check it.
When it does not fit: Nothing major; the drugs behind the "3 drugs" claim are not all named.
Cancer immunotherapy developer. Slide titled "Veteran Management Team / Board".
Greenwich LifeSciences deck, slide 3. Exact stored slide matched to this analysis.
Our analysis: Each role an investor expects in a clinical-stage company is filled: chairman, CEO, chief medical officer and a clinical and regulatory lead with 200 trials.
Evidence and limitation: Years, companies led and a count of clinical trials, with a named clinical and regulatory lead.
What a founder can adapt: Give each person one count like trials run or companies led.
Supporting analysis
What the deck claims: David McWilliams, "Chairman, Board": "40 years of start-up / CEO experience", "CEO of 2 private and 3 public biotech companies". Snehal Patel, "CEO, Board": "30 years of pharma / Wall Street experience". Joe Daugherty, M.D., "CMO, Board": "35+ years of biopharma experience", "Assisted over 20 public and private companies". Jaye Thompson, Ph.D., "VP Clinical & Regulatory": "30 years of active involvement in over 200 clinical trials for drugs, biologics and devices", "Founder of multiple CROs". Logos include Abbott, Bayer, JPMorgan Chase and MD Anderson.
Presentation choice: Investors want to see who will run the trials; this slide names that person and gives a number.
When it does not fit: Board members with names only at the bottom of the slide.
Regenerative medicine company, publicly listed. Slide titled "Experienced Leadership Team".
BioTime deck, slide 5. Exact stored slide matched to this analysis.
Our analysis: The slide shows long, relevant experience and marks who joined recently, but it gives no results such as trials completed or products approved.
Evidence and limitation: Years in the field and past employers as logos, with management and board separated.
What a founder can adapt: Swap one logo per person for one achievement.
Supporting analysis
What the deck claims: "Management": Adi Mohanty, "Co-Chief Executive Officer", "16 years of experience in executive and management positions" (Shire, Baxter logos); Michael D. West, Ph.D., "Co-Chief Executive Officer", "26 years of experience in regenerative medicine and management"; Oscar Cuzzani, M.D., Ph.D., "30 years of experience as a physician and in clinical development" (NIH, AbbVie, Allergan logos). "Board of Directors" listed with current roles, including "Former CEO, Shire plc". "Shading = Joined in 2013 or later".
Presentation choice: Big-company logos signal that the team knows how large drug companies work.
When it does not fit: Relying on logos and years alone.
Athersys deck, slide 6. Exact stored slide matched to this analysis.
Our analysis: The table is easy to scan and includes a named regulatory lead, but the logos say where people worked, not what they did there.
Evidence and limitation: Names, roles, a regulatory lead and past employers as logos.
What a founder can adapt: Add a short text column: one result per person.
Supporting analysis
What the deck claims: A table with "Name", "Title" and "Prior Experience": Gil Van Bokkelen, PhD, "Chairman & CEO"; William BJ Lehmann, "President & COO"; John Harrington, PhD, "CSO Exec. VP, Board member"; Manal Morsy, MD, PhD, "Senior VP Global Regulatory Affairs"; Laura Campbell, "Senior VP Finance". Prior experience is shown only as logos, such as Stanford, McKinsey & Company, Amgen, Merck and EY.
Presentation choice: A regulatory role is a good sign in biotech; the slide would be stronger with what that person got approved.
When it does not fit: Logo-only experience columns.
Interpace Diagnostics deck, slide 3. Exact stored slide matched to this analysis.
Our analysis: For a diagnostics company, a pathologist founder and a commercial lead who has worked with insurers are the right mix, but the dense paragraphs hide it.
Evidence and limitation: Prose bios with named companies, a publication count and a commercial lead with payer experience.
What a founder can adapt: Turn each paragraph into two short lines with the most relevant fact first.
Supporting analysis
What the deck claims: Jack E. Stover, "President & CEO since December 2015", "Prior Director of PDI", "Previously President & CEO of Antares Pharma". Sydney Finkelstein, MD, "CMO and CSO, Founder of RedPath", "a board certified anatomic pathologist", "authored over 200 peer review manuscripts". Greg Richard, "Sr. VP Commercial Services", "VP of Managed Care for Quest". Jim Early, "Chief Financial Officer".
Presentation choice: Diagnostics companies need insurers to pay for tests; the slide shows someone who has done that work at Quest and Aetna.
When it does not fit: Long paragraphs that bury the key credential.
Early-stage drug and digital health developer. Slide titled "Team: Co-Founders / Directors". (weaker)
mHealthPharma deck, slide 3. Exact stored slide matched to this analysis.
Our analysis: Included for contrast: two of three co-founders are software engineers, and nobody is shown to have run a trial or worked with regulators. The deck's next slide lists advisors to cover that gap.
Evidence and limitation: Degrees and years; one medical founder; no clinical trial or regulatory experience shown.
What a founder can adapt: Say which team member owns trials and approval, even if they joined recently.
Supporting analysis
What the deck claims: Dr. Steven Orlov, "Co-Founder": "MD (Endocrinology) from University of Toronto", "MSc in Clinical Epidemiology from McMaster University", "Multiple research publications". Alex Berlin, "Co-Founder": "Software Engineer and Architect with 30+ years experience". Leonid Orlov, "Co-Founder": "Computer programmer with 25+ years experience". Isaak Karaev, "Independent Director": "Serial Entrepreneur", "4 Exits".
Presentation choice: Investors notice when clinical and regulatory experience sits only with advisors.
When it does not fit: Leaving the clinical path to an advisors slide.
Biotech developing protein therapies. Slide titled "Experienced Management Team". (weakest)
Medgenics deck, slide 4. Exact stored slide matched to this analysis.
Our analysis: Included for contrast: some strong facts are here, but more than twenty names in small type make it hard to see who runs the company or who has taken a product through the FDA.
Evidence and limitation: Many names, short affiliations and one sale value.
What a founder can adapt: Put management on the team slide and move the board and advisors to a second slide.
Supporting analysis
What the deck claims: Subtitle: "Extensive experience in healthcare industry, founded, operated and led firms to M&A". Three columns: "Board of Directors" (for example Gary Brukardt, "former CEO Renal Care Group (sold for $3.5B)"), "SAB/Advisors" (for example "Andra E. Miller PhD – Former FDA"), and "Management" (Andrew L. Pearlman PhD, "Founder President & CEO", and others with titles and one prior employer).
Presentation choice: When everyone is on one slide, no one stands out.
When it does not fit: Three groups crammed into narrow columns.
Whether an investor can see approval experience, clinical and regulatory ownership, and something checkable about the team.
Example
Business
Approval experience
Clinical / regulatory owner
Checkable facts
Tiziana
Drug developer
Yes (named drug)
CEO & CSO
Drug, company sale
Greenwich LifeSciences
Cancer immunotherapy
Not named
Yes (200+ trials)
Trial count, companies led
BioTime
Regenerative medicine
Not shown
Clinical development head
Years, employer logos
Athersys
Cell therapy
Not shown
Regulatory SVP
Employer logos
Interpace
Diagnostics
Not shown
Pathologist CMO
Companies, publications
mHealthPharma
Drug and digital health
Not shown
Not on team
Degrees, exits
Medgenics
Protein therapies
Former FDA advisor
Hard to tell
One sale value
Key Takeaways
Name the drugs, devices or tests the team has taken to approval.
Show who owns clinical trials and who owns regulatory work.
Give a result for each person, not only years of experience.
Separate management from the board and advisors.
Keep logos as support, not the whole bio.
Build your biotech team slide
Show who has taken a product through the clinic, then who will do it this time.
Approvals. Which drugs, devices or tests has anyone on the team helped get approved?
Clinical. Who will run your trials, and how many have they run before?
Regulatory. Who owns regulatory filings, and which agencies have they worked with?
Capital. Who has raised money for or sold a biotech company, and for how much?
Science. Who invented or leads the core science, and where did it come from?
Copyable framework: Headline: [approvals or trials the team has delivered]. [Name], CEO: [company led], [result]. [Name], CMO: [trials run], [approval]. [Name], Regulatory: [agency], [filing].
Illustrative example 1 — written by us
Before: Alex Berlin, Co-Founder: Software Engineer and Architect with 30+ years experience.
After: [Name], Chief Medical Officer: ran [number] trials in [area] at [company], [approval]. Alex Berlin, CTO: [platform built], [scale].
What improved: Our illustrative rewrite; the bracketed details are placeholders, not mHealthPharma's facts. It shows who owns the clinical path.
What this guide adds
The general team slide guide covers any company, and the healthcare team guide covers care delivery and digital health. Biotech has a narrower question: can this team take a product through trials and regulators, and has it done so before?
Our library's biotech tag covers drug developers, diagnostics companies and regenerative medicine. Several decks here come from publicly listed companies, which tend to show larger teams and boards. We note each company's business in the examples.
How we read each slide
We quote the text on the stored slide images. We have not checked any approval, trial count, employer, sale or experience claim.
Common mistakes
No approval experience shown. Name any product the team has helped get approved.
No clinical or regulatory owner. Name the person who will run trials and filings.
Logos instead of results. Say what each person achieved at the company.
Board and advisors crowd the team. Put them on a separate slide or a smaller row.
Dense paragraphs. Lead each bio with the most relevant fact.
Diagnostic checklist
Drugs, devices or tests the team has helped bring to market.
A named clinical lead and a named regulatory lead.
One result per person: a trial, an approval, a sale.
Management apart from board and advisors.
Where the core science came from.
Frequently asked questions
What should a biotech team slide show?
Who has taken a product through trials and regulators before, with the product named. Tiziana's CEO is shown as the inventor of an approved drug, TRULANCE.
Is it enough to list years of experience?
It helps, but results are stronger. Greenwich LifeSciences adds that its clinical lead was involved in over 200 clinical trials.
Can advisors cover clinical and regulatory experience?
They can help, but investors want someone on the team to own it. mHealthPharma's co-founders include two software engineers, and trial experience sits with its advisors.
How we chose these examples
Corpus: published pitch deck teardowns on StartupFundraising.com. Founder-uploaded private decks are excluded.
Selection (2026-09-27): we searched extracted slide text in decks tagged biotech for team, founders, management or leadership together with CEO, CTO or co-founder. Seventeen slides matched; fifteen had stored images and were reviewed as images.
Kept seven. Left out: Tiziana's other listed deck p3 (a near-copy of the chosen slide), MDNA p3 and p4 (a diagnostics team split over two slides), mHealthPharma p4 (an advisors slide), Ablelife p3 (a team whose listed experience is in water treatment and IT), and slides that were not team slides (Cancer Genetics p3, Diplomat p3, Bijana p2). No uploads were requested.
Review: stored slide text and images were checked on 2026-09-27 and matched to company, deck and slide number (editorial model review). No person has yet completed an editorial review of this page.
Claims are as shown on the slides; we have not verified them. We make no claim that any slide caused a fundraising outcome.
